Abilify Patent Re-Examination Under Way, Bristol Discloses
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb expects the Patent & Trademark Office to reaffirm the patentability of Abilify (aripiprazole) when it completes a re-examination next year